Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:57:01.086Z.
Consensus retrieved: 2026-10-06T12:12:10.949Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:57:01.086Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76b79f67d555c15c1d19b9a53ec9076b1294dcb64452140a50102a9ec63499e7
Forward PE Ratio (N/A) = Dated Quote Price ($6.37) / Consensus Forward EPS ($-10.75)
FORWARD PE RATIO
N/A
GT Biopharma, Inc.
Market Cap
$8.04M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GT Biopharma, Inc. (GTBP) | $8.04M | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.05M | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.14M | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.37, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-10.75 | $-10.75 – $-10.75 | 1 | n/m |
| 2027-12-31 | $-8.00 | $-8.00 – $-8.00 | 1 | n/m |
| 2028-12-31 | $-7.00 | $-7.00 – $-7.00 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
